Analysis of the anticancer drugs etoposide (VP 16-213) and teniposide (VM 26) by high-performance liquid chromatography with fluorescence detection

Strife, Robert J.; Jardine, Lynne; Colvin, Michael

doi:10.1016/s0378-4347(00)80153-x

Cited by 50 publications

(17 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Separated plasma was stored at À801C until measurement. Concentrations of t-Pt and f-Pt were determined by flameless atomic absorption spectrophotometry (LeRoy et al, 1977), and those of etoposide were determined by high-performance liquid chromatography (Strife et al, 1981). Pharmacokinetics data were analysed according to the previously reported method (Yamaoka et al, 1978).…”

Section: Pharmacokinetics Studymentioning

confidence: 99%

Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer

et al. 2003

View full text Add to dashboard Cite

Cancer chemotherapy for haemodialysis patients has never been established. To elucidate the feasibility of cisplatin-based combination chemotherapy for haemodialysis patients with lung cancer, a dose escalation study was conducted. Five haemodialysis patients with lung cancer were treated with cisplatin and etoposide. A starting dose of 40 mg m À2 of cisplatin on day 1 and 50 mg m À2 of etoposide on days 1, 3 and 5 were administered as the first course for the first patient. Membrane haemodialysis was regularly performed three times a week and soon after the completion of therapy. By monitoring toxicity and pharmacokinetics data, the dose was escalated course by course and patient by patient. Dose escalation was completed for the first two patients resulting in full-dose chemotherapy consisting of 80 mg m À2 of cisplatin on day 1 and 100 mg m À2 of etoposide on days 1, 3 and 5. Multiple courses of the full-dose chemotherapy were administered to the other three patients. Toxicity was manageable and tolerable for all. Pharmacokinetics data were comparable to those from patients with normal renal function, except for potential long-lasting higher levels of free platinum in the renal insufficiency group. In conclusion, this standard-dose combination chemotherapy was feasible even for haemodialysis patients.

show abstract

Section: Pharmacokinetics Studymentioning

confidence: 99%

Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Several methods for the determination of etoposide include HPLC with UV detection [5][6][7][8], fluorescence detection [9], and electrochemical detection [10][11]. It has also been determined by LC-MS method [12][13] and ELISA method [14].…”

Section: Peak Identificationmentioning

confidence: 99%

HPLC Determination of Etoposide in Injectable Dosage Forms

Hayat

Ashraf

ur-Rehman

et al. 2011

J. Chil. Chem. Soc.

View full text Add to dashboard Cite

1.The present study describes a direct and an alternative HPLC method for the determination of etoposide in injectable dosage forms. Etoposide, an antineoplastic drug, was eluted through C 18 ODS Hypersil column of 250 × 4.6 mm id with 5 µm particle size using simple mobile phase of methanol: water (1:1, v/v) at a flow rate of 1.0 mL min -1 and detected at 204 nm. The limit of detection of etoposide was 0.03 µg mL -1. The proposed method was found linear in the range of 0.25 µg mL -1 to 62.5 µg mL -1 and CV was 1.3% at 0.25 µg mL -1 , 0.48% at 3.90 µg mL -1 and 0.13% at 62.5 µg mL -1 . The accuracy of the developed method for two injectable dosage forms was 99.4 and 99.7% with RSD of 0.3%. The validation results and statistical data demonstrate that the method is simple, cost effective, reproducible and suitable in quality analysis of the active ingredient and dosage form.

show abstract

“…In order to understand the distribution of etoposide into tumor it is necessary to develop a sensitive method for quantifying the drug in different biological matrices. Several methods have been used for the determination of etoposide in plasma using high‐performance liquid chromatography (HPLC) with UV detection (Holthius et al ., ; Shirazi et al ., ; Kato et al ., ; Dhanaraju et al ., ; Zhang et al ., ), fluorescence detection (Strife et al ., ; Werkhoven‐Goewie et al ., ; Manouilov et al ., ) and electrochemical detection (Duncan et al ., ; Cai et al ., ; Pérez‐Urizar et al , ). Modern chromatographic methods, such as high‐performance liquid chromatography tandem mass spectrometry (HPLC‐MS/MS) and ultra‐performance liquid chromatography quadrupole time of flight mass spectrometry (UPLC‐qTOF‐MS/MS) have also been published for etoposide quantification in biological matrices (Liu et al ., ; Sachin et al ., ).…”

Section: Introductionmentioning

confidence: 99%

HPLC‐UV method for quantifying etoposide in plasma and tumor interstitial fluid by microdialysis: application to pharmacokinetic studies

Pigatto

Mossmann

Costa

2014

Biomedical Chromatography

View full text Add to dashboard Cite

A simple and sensitive bioanalytical method was developed and validated for determination of etoposide in plasma and microdialysis samples of Walker-256 tumor-bearing rats. A microdialysis probe was implanted in the center of a subcutaneous tumor and Ringer's solution was used as perfusion medium. Chromatographic separation was conducted on a Shimadzu CLC-C8 column using a mobile phase consisting of water-acetonitrile (70:30; v/v) adjusted to pH 4.0 ± 0.1 with formic acid at a gradient flow rate of 1.0-0.6 mL/min, an injection volume of 30 μL and UV detection at 210 nm. Microdialysate samples were analyzed without processing and plasma samples (100 μL) were spiked with phenytoin as internal standard (IS) (1 µg/mL) followed by extraction with tert-butyl methyl ether. The organic layer was evaporated and reconstituted with 100 μL of mobile phase before injection. The methods for plasma and microdialysate were linear in the ranges of 25-10,000 ng/mL and of 10-1500 ng/mL, respectively. All the validation parameters such as intra- and inter-day precision and accuracy and stability were within the limits established by international guidelines. The present method was successfully applied in the investigation of etoposide pharmacokinetics in rat plasma and microdialysate tumor samples following a single 15 mg/kg intravenous dose.

show abstract

Analysis of the anticancer drugs etoposide (VP 16-213) and teniposide (VM 26) by high-performance liquid chromatography with fluorescence detection

Cited by 50 publications

References 3 publications

Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer

Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer

HPLC Determination of Etoposide in Injectable Dosage Forms

HPLC‐UV method for quantifying etoposide in plasma and tumor interstitial fluid by microdialysis: application to pharmacokinetic studies

Contact Info

Product

Resources

About